Compare Devon Energy Corp (DVN) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Devon Energy Corp trades at $50.07 (market cap $55.23B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Devon Energy Corp is far larger — about 56.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Devon Energy Corp pays a 2.55% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Devon Energy Corp for 136 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| DVN | MRVI | |
|---|---|---|
Market Cap | $55.23B | $972.90M |
Volume | 10,032,111 | 4,325,710 |
Sector | Energy | Health |
52-Week High | $52.07 | $9.00 |
52-Week Low | $31.74 | $2.83 |
Typical Hold Time | 136 Days | 0 Days |
Enterprise Value | $65.97B | $1.08B |
Dividend Yield | 2.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $49.92, up 1.96% with strong bullish technical signals from moving averages. The stock shows attractive valuation metrics including a P/E of 10.92 and P/S of 1.79, while maintaining solid profitability with 16.67% net margins. Recent activist investor pressure for strategic alternatives and potential asset sales create catalysts, though the company faces earnings volatility with mixed quarterly results including a Q1 miss but Q2 beat.
DVN presents value opportunity with 25% upside to consensus target of $62.53, supported by 72% analyst buy ratings. Key risks include oil price sensitivity and execution on asset sales, while the improving cash flow trend and Permian Basin focus provide fundamental support. The combination of reasonable valuation and strategic optionality makes DVN compelling for energy investors.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
